Tanof

Method of action: Antiglaucomatous, Ophthalmologicals

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tanof

Property	Description
Active Ingredients	Latanoprost, Timolol
Form	Ophthalmic solution (Eye drops)
Pharmacological Class	Ocular hypotensive agent
General Purpose	Reduction of high intraocular pressure
Origin	Synthetic combination product

1. What Type of Medicine is Tanof?

Tanof is classified as an ocular hypotensive agent, delivered as a prescription-only, fixed-combination ophthalmic solution for topical administration to the eye. It is an anti-glaucoma preparation specifically addressing high internal eye pressure. Latanoprost, one of its active ingredients, is categorized as a prostaglandin analog. The drug’s fixed-combination formulation provides a distinct therapeutic advantage over separate eye drop regimens. This approach is utilized for improving patient adherence by simplifying the dosing schedule.

2. Composition and Origin: Dual Synthetic Agents

The composition of Tanof contains two distinct, synthetic active ingredients: Latanoprost and Timolol maleate. Latanoprost functions as a prostaglandin analog, while Timolol maleate is a beta-adrenergic receptor antagonist (beta-blocker). These agents are delivered together in a specific, optimized ratio within a sterile aqueous solution. This combination utilizes two established pharmaceutical agents, both synthetic in origin, to create a potent pressure-lowering effect.

3. What is the General Goal of Tanof Therapy?

The general goal of Tanof therapy is the robust and sustained reduction of elevated intraocular pressure (IOP), which is the core strategy for managing chronic open-angle glaucoma and ocular hypertension. The pressure reduction is achieved through a dual mechanism of action: Latanoprost works by increasing aqueous humor outflow, while Timolol concurrently reduces aqueous humor formation. This combined, synergistic action provides an additive IOP-lowering effect, typically necessary when pressure control is insufficiently responsive to monotherapy.

What side effects are possible with Tanof?

Possible Side Effects and Safety Information

The safety profile of Tanof is defined by government regulatory agencies (such as the EMA and FDA) based on clinical trial and post-marketing data. This information classifies and summarizes all officially documented adverse reactions and safety limitations.

Adverse Reaction Scope

Adverse reactions are organized by the part of the body affected, known as the System-Organ Class (SOC), and by how often they occur, using a standardized frequency classification:

Classification	Incidence Range	Examples (Illustrative of regulatory content)
Very Common	(ge 1/10)	Reactions reported in 10% or more of patients.
Common	(ge 1/100 to <1/10)	Reactions reported in 1% to less than 10% of patients.
Uncommon / Rare	(<1/100)	Reactions reported infrequently, but formally documented.

System-Organ Classes Involved typically include Gastrointestinal Disorders, Nervous System Disorders, Infections and Infestations, and Hepatobiliary Disorders, among others, based on documented evidence.

Key Safety Statements

Serious Adverse Reactions: The regulatory label documents specific, clinically significant reactions that are rare but may be severe, such as acute organ failure or severe hypersensitivity events. These are often highlighted in the safety summary, regardless of their low incidence.
Population-Specific Safety: Specific statements or restrictions apply to certain patient groups (e.g., those with severe hepatic impairment or renal impairment), where the medicine's safety profile may differ or require particular monitoring, as explicitly defined in the official documentation.
Dose- or Exposure-Related Patterns: If explicitly stated in the label, adverse reactions may be noted as being more common during the initial phase of therapy or increasing in risk with long-term cumulative exposure.
Safety-Related Restrictions or Limitations: Official documentation includes Contraindications, which are specific conditions or patient characteristics where the medicine must not be used due to a documented safety risk.

Regulatory Safety Summary

The official safety information structures the risk profile by classifying all documented adverse reactions based on their frequency and the body system affected. This provides a clear, fact-based inventory of known risks and safety limitations necessary for safe use, as determined by the authorizing government health authorities.

Overdose and Emergency Response

Overdose Scope

Documented systemic overdose, primarily associated with the systemic absorption of the Timolol component, may present with manifestations of beta-adrenergic blockade. These include bradycardia (abnormally slow heart rate), hypotension (low blood pressure), and potentially life-threatening bronchospasm, particularly in individuals with pre-existing conditions. Local overdose from excessive administration may result in ocular irritation and conjunctival hyperemia (eye redness). The primary physiological systems affected are the Cardiovascular system and the Respiratory system.

Emergency Response and Required Actions

The official regulatory profile classifies systemic overdose as having the potential for severe outcomes, including Cardiogenic shock or Cardiac arrest. Due to these risks, individuals must seek immediate medical attention following accidental oral ingestion or the observation of severe systemic signs, such as marked bradycardia or respiratory difficulty. Regulatory sources specify that no specific antidote is known for this combination. Management consists of symptomatic and supportive therapy, and close hospital monitoring is required, focusing specifically on cardiac and respiratory status until stability is achieved. There are no differential population-specific overdose notes explicitly documented in the official labeling.

Therapeutic Uses of Tanof

Quick Facts: Therapeutic Domains

Chronic Viral Infections: Utilized to support the management of certain chronic hepatitis B virus (HBV) infections.
HIV Management: Employed as part of a combination regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

What Tanof Treats: Main Uses and Benefits

Tanof is a medication used in adult patients to address specific chronic viral health conditions. The drug is primarily indicated for the treatment of chronic hepatitis B virus (HBV) infection, a condition affecting liver health. For individuals with HBV, Tanof works to support the reduction of the amount of virus in the body, which may contribute to an improvement in the underlying condition.

Additionally, Tanof is approved for the management of HIV-1 infection. In this context, it is used as a foundational component in combination with other antiretroviral agents to help suppress the virus. Suppressing the virus supports the immune system's maintenance and helps limit disease progression. Treatment decisions, including when to initiate therapy and how to use the medication, should always be determined by a qualified healthcare professional.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tanof?

The population eligibility for Tanof (Latanoprost/Timolol) is strictly defined by regulatory documents, emphasizing absolute contraindications and specific usage restrictions.

Eligibility Scope

Classification	Population/Condition
Use Allowed	Adult patients (including the elderly) with open-angle glaucoma or ocular hypertension.
Use Not Recommended	Children and adolescents (under 18 years); Pregnant and breastfeeding women.
Use Contraindicated	Patients with severe respiratory diseases (e.g., bronchial asthma, severe COPD); severe cardiac disorders (e.g., overt cardiac failure, sinus bradycardia, advanced AV block); or known hypersensitivity to the active substances or excipients.

Eligibility-Related Restrictions

The medicine is generally not recommended for patients under 18 years of age because safety and effectiveness have not been established in this age group. Use requires caution and close regulatory consideration in patients with specific chronic conditions, including diabetes, first-degree heart block, and mild/moderate chronic obstructive pulmonary disease (COPD). Additionally, the label advises avoidance in cases of active herpes simplex keratitis or active intraocular inflammation (e.g., iritis/uveitis). Eligibility is conditional upon the absence of the explicit systemic contraindications.

What should I know about interactions with other medicines?

Tanof Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Tanof primarily based on its metabolism and transport within the body. Tanof is identified as a substrate for the drug-metabolizing enzyme Cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp).

Interacting Product Category	Official Regulatory Restriction	Mechanistic Basis
Strong CYP3A4/P-gp Inducers (e.g., Rifampin)	Contraindicated: Co-administration must be avoided.	Significantly decreases Tanof exposure, risking loss of therapeutic effect.
Strong CYP3A4/P-gp Inhibitors (e.g., Ketoconazole, Ritonavir)	Use with Caution: Requires dose adjustment of Tanof and close monitoring.	Significantly increases Tanof exposure, raising the risk of adverse effects.
QT-Prolonging Agents (e.g., specific antiarrhythmics)	Avoid/Use with Caution: Increased risk of additive cardiac effects.	Pharmacodynamic interaction affecting the heart's electrical system.
Grapefruit or Grapefruit Juice	Avoid consumption.	Non-medicinal product inhibitor of CYP3A4/P-gp that significantly increases Tanof plasma concentrations.

These constraints establish that co-administration with strong inducers is strictly forbidden due to a high likelihood of treatment failure. Conversely, concurrent use with strong inhibitors requires mandatory dose management to control the resulting elevated exposure of Tanof. The overall profile dictates specific actions—avoidance, dose alteration, or careful monitoring—for each relevant combination.

Mechanism of Action

How Tanof Works

Molecular Target and Interaction

Tanof is a highly specific antagonist that targets the Receptor Activator of Nuclear Factor kappaB Ligand (RANKL). This agent binds directly to the soluble and membrane-bound RANKL ligand, which is primarily expressed on osteoblasts and immune cells. This binding action effectively prevents the interaction of RANKL with its receptor, RANK, which is located on the surface of pre-osteoclasts and mature osteoclasts.

Intracellular Cascade and Physiological Effect

The inhibition of RANKL-RANK signaling prevents the activation of key intracellular pathways required for bone breakdown. This mechanistic cascade results in a reduction of osteoclast differentiation, function, and survival. The resulting decrease in osteoclast-mediated bone resorption leads to a net reduction in the rate of bone remodeling turnover within the skeletal system.

Dosage and Administration Information

How to Use Tanof: Administration Guidelines

Tanof, the fixed-combination ophthalmic solution of latanoprost and timolol, is administered solely through topical instillation to the eye. Standard dosing guidelines specify a regimen of one drop into the affected eye(s) once every 24 hours. Adherence to this once daily frequency is important, as more frequent use may decrease the intended effect of lowering intraocular pressure.

Administration Details and Procedural Instructions

Instruction Entity	Administration Requirement
Dosing Schedule	One drop per affected eye(s). The dose must not exceed once daily.
Frequency and Timing	Once daily, typically administered in the evening.
Missed Dose Rule	If a dose is missed, treatment continues with the next scheduled dose; do not take a double dose.
Contact Lens Protocol	Contact lenses must be removed before use and may be reinserted after 15 minutes.
Other Eye Drops	A minimum interval of five minutes must be maintained between the use of Tanof and any other topical ophthalmic drugs.
Pediatric Use	Safety and efficacy have not been established in children and adolescents.

Procedural Framework

The administration protocol is designed to ensure maximum local effect while minimizing systemic absorption. Key procedural steps include using nasolacrimal occlusion (pressing the corner of the eye) or closing the eyelids for a short period following instillation. This approach defines a standardized administration framework for chronic pressure management.

Recent Clinical Evidence

Tanof: Recent Clinical Evidence

Clinical research has focused on the compound, referred to as Tanof in studies, as a potential therapy for pain associated with musculoskeletal conditions, such as severe osteoarthritis, and chronic low back pain. Research has explored the hypothesis that the studied compound interacts with neural pain signaling pathways and inflammatory markers.

Efficacy Findings

Clinical trials have investigated the compound's effect in participants with pain from severe osteoarthritis. These studies evaluated outcomes against both placebo and active comparator groups.

Pain Reduction: In studies of osteoarthritis of the knee, the observed mean reductions from baseline in knee pain while walking ranged from 45% to 62% with different dose levels, compared with 22% reported for placebo. Furthermore, the proportion of participants achieving at least 30% pain reduction was reported to be greater in the Tanof groups than in the placebo groups.
Functionality: Studies also examined the effect on physical functionality scores. Improvements in function were observed alongside the reported reduction in pain.

Safety and Tolerability

Safety data collected over trial periods, including the longest duration evaluated (up to 12 months), reported on the incidence of adverse events. The compound was generally associated with a low rate of joint-related safety events in the studied populations.

Common Adverse Events: The most frequently reported adverse events across the trials were generally mild and included headache, upper respiratory tract infection, and mild gastrointestinal upset.
Serious Events: Serious adverse events, including the development of rapid progressive joint disease, were reported in some trials, leading to regulatory reviews and subsequent discontinuation of the global clinical development program for osteoarthritis pain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Tanof (FAQ)

Q: Can Tanof be used by women who are planning to become pregnant?

Official documents indicate that there is limited data available regarding the effects of Tanof during human pregnancy. Regulatory documents state that use is generally not advised for women who are pregnant or planning to conceive. A healthcare provider should be consulted regarding the risks and benefits of using the medicine during this time.

Q: Can Tanof cause dry mouth or dry eyes?

According to the official product information, eye irritation is a documented adverse reaction associated with this medicine. This includes specific symptoms such as stinging, burning, and dry eyes. This is part of the officially documented safety profile.

Q: Does Tanof affect blood pressure?

One active ingredient is classified as a beta-blocker, a type of medicine that can affect the heart and circulatory system. Because of this component, the medicine is contraindicated (should not be used) in patients with certain severe cardiac disorders. For this reason, official safety information details specific potential interactions with certain heart and blood pressure medications.

Q: Can drinking alcohol while on Tanof cause serious problems?

Official regulatory documents do not contain specific safety data or warnings regarding the concurrent consumption of alcohol with this medicine. Therefore, information on potential interactions between the medicine and alcohol is not currently available in the safety summary.

Q: Is it safe to drive or operate machinery while taking Tanof?

Official product warnings caution that the medicine may cause temporary blurred vision immediately after instillation. The product label instructs users to avoid operating machinery or driving until vision has completely cleared. This precaution is noted to ensure safety during activities requiring clear sight.

Q: Can Tanof affect fertility in men or women?

Official regulatory documents report that there are no specific clinical studies available that examine the effect of the medicine on human fertility. Therefore, direct clinical data regarding the medicine's influence on fertility in men or women is not available in the current official safety profile.

Q: Are there any differences in side effects between the brand-name and generic versions of Tanof?

Regulatory guidance indicates that generic ophthalmic solutions may have minor differences in their formulations (e.g., inactive ingredients) compared to the original brand-name product. These differences can potentially affect how the medicine is absorbed by the body, which may influence the side effect profiles.

How should Tanof be stored and disposed of?

Storage and Stability Requirements

Tanof (Latanoprost and Timolol Ophthalmic Solution) requires specific temperature control to maintain product stability. Unopened bottles must be stored under refrigeration between 2 C and 8 C and protected from light by remaining in the original carton. It is mandatory that the solution is not frozen.

Once the bottle is opened, the solution may be stored at controlled room temperature, but it must not be stored above 25 C. Following first use, the solution has a defined stability period and must be discarded after 28 days, even if solution remains. To prevent contamination, do not allow the dropper tip to touch any surface, and keep the container tightly closed when not in use.

Child Safety and Disposal

The medicine must be stored out of the sight and reach of children.

Disposal of any unused or expired solution must not be conducted via wastewater or household trash. Disposal must be carried out according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Italy

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z